MX2007003505A - Combinacion que comprende zd6474 e imatinib. - Google Patents
Combinacion que comprende zd6474 e imatinib.Info
- Publication number
- MX2007003505A MX2007003505A MX2007003505A MX2007003505A MX2007003505A MX 2007003505 A MX2007003505 A MX 2007003505A MX 2007003505 A MX2007003505 A MX 2007003505A MX 2007003505 A MX2007003505 A MX 2007003505A MX 2007003505 A MX2007003505 A MX 2007003505A
- Authority
- MX
- Mexico
- Prior art keywords
- imatinib
- human
- combination
- antiangiogenic
- warm
- Prior art date
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 title abstract 6
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title abstract 6
- 229960002411 imatinib Drugs 0.000 title abstract 6
- 241001465754 Metazoa Species 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000005855 radiation Effects 0.000 abstract 2
- 230000001603 reducing effect Effects 0.000 abstract 2
- 230000008728 vascular permeability Effects 0.000 abstract 2
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0421438A GB0421438D0 (en) | 2004-09-27 | 2004-09-27 | Combination therapy |
| GB0506726A GB0506726D0 (en) | 2005-04-01 | 2005-04-01 | Combination therapy |
| PCT/GB2005/003673 WO2006035204A2 (en) | 2004-09-27 | 2005-09-23 | Combination comprising zd6474 and an imatinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007003505A true MX2007003505A (es) | 2007-05-10 |
Family
ID=35924044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007003505A MX2007003505A (es) | 2004-09-27 | 2005-09-23 | Combinacion que comprende zd6474 e imatinib. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20080119479A1 (enExample) |
| EP (1) | EP1804802A2 (enExample) |
| JP (1) | JP2008514577A (enExample) |
| KR (1) | KR20070072543A (enExample) |
| AU (1) | AU2005288737B2 (enExample) |
| BR (1) | BRPI0516052A (enExample) |
| CA (1) | CA2578956A1 (enExample) |
| IL (1) | IL181609A0 (enExample) |
| MX (1) | MX2007003505A (enExample) |
| NO (1) | NO20071428L (enExample) |
| WO (1) | WO2006035204A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| DE602004032310D1 (de) * | 2003-02-13 | 2011-06-01 | Astrazeneca Ab | Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| JP2007526886A (ja) * | 2003-07-10 | 2007-09-20 | アストラゼネカ アクチボラグ | 血管新生および／または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体ｚｄ６４７４の使用 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| CA2631764A1 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of zd6474 and pemetrexed |
| WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
| EP3352107B1 (en) | 2008-03-03 | 2025-10-22 | NIKE Innovate C.V. | Interactive athletic equipment system |
| US8628453B2 (en) | 2008-12-05 | 2014-01-14 | Nike, Inc. | Athletic performance monitoring systems and methods in a team sports environment |
| US20100184564A1 (en) | 2008-12-05 | 2010-07-22 | Nike, Inc. | Athletic Performance Monitoring Systems and Methods in a Team Sports Environment |
| US8231506B2 (en) | 2008-12-05 | 2012-07-31 | Nike, Inc. | Athletic performance monitoring systems and methods in a team sports environment |
| CA2955632A1 (en) | 2010-11-10 | 2012-05-18 | Nike Innovate C.V. | Systems and methods for time-based athletic activity measurement and display |
| EP2676212B1 (en) | 2011-02-17 | 2022-03-16 | NIKE Innovate C.V. | Selecting and correlating physical activity data with image data |
| KR101386697B1 (ko) | 2012-06-18 | 2014-04-18 | 아주대학교산학협력단 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| CA3280124A1 (en) | 2013-07-31 | 2025-10-31 | Avalyn Pharma Inc. | Aerosol imatinib compounds and uses thereof |
| KR101778004B1 (ko) | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
| EP3658190B1 (en) | 2017-07-26 | 2025-10-01 | Oncosol Limited | Liquid dosage forms of imatinib |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1244647E (pt) * | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| AU2003231098A1 (en) * | 2002-04-25 | 2003-11-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| AU2003249000B2 (en) * | 2002-08-09 | 2007-04-05 | Astrazeneca Ab | Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| DE602004032310D1 (de) * | 2003-02-13 | 2011-06-01 | Astrazeneca Ab | Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11 |
| JP2007526886A (ja) * | 2003-07-10 | 2007-09-20 | アストラゼネカ アクチボラグ | 血管新生および／または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体ｚｄ６４７４の使用 |
| EP1796672A1 (en) * | 2004-09-27 | 2007-06-20 | AstraZeneca AB | Cancer combination therapy comprising azd2171 and imatinib |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| CA2631764A1 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of zd6474 and pemetrexed |
-
2005
- 2005-09-23 KR KR1020077009369A patent/KR20070072543A/ko not_active Withdrawn
- 2005-09-23 WO PCT/GB2005/003673 patent/WO2006035204A2/en not_active Ceased
- 2005-09-23 BR BRPI0516052-9A patent/BRPI0516052A/pt not_active IP Right Cessation
- 2005-09-23 MX MX2007003505A patent/MX2007003505A/es not_active Application Discontinuation
- 2005-09-23 JP JP2007532963A patent/JP2008514577A/ja active Pending
- 2005-09-23 AU AU2005288737A patent/AU2005288737B2/en not_active Ceased
- 2005-09-23 EP EP05786268A patent/EP1804802A2/en not_active Withdrawn
- 2005-09-23 CA CA002578956A patent/CA2578956A1/en not_active Abandoned
- 2005-09-23 US US11/663,913 patent/US20080119479A1/en not_active Abandoned
-
2007
- 2007-02-27 IL IL181609A patent/IL181609A0/en unknown
- 2007-03-16 NO NO20071428A patent/NO20071428L/no not_active Application Discontinuation
-
2009
- 2009-06-05 US US12/479,131 patent/US20100069398A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20071428L (no) | 2007-04-02 |
| KR20070072543A (ko) | 2007-07-04 |
| EP1804802A2 (en) | 2007-07-11 |
| WO2006035204A3 (en) | 2006-10-19 |
| AU2005288737A1 (en) | 2006-04-06 |
| US20100069398A1 (en) | 2010-03-18 |
| IL181609A0 (en) | 2007-07-04 |
| CA2578956A1 (en) | 2006-04-06 |
| BRPI0516052A (pt) | 2008-08-19 |
| AU2005288737B2 (en) | 2008-08-14 |
| WO2006035204A2 (en) | 2006-04-06 |
| US20080119479A1 (en) | 2008-05-22 |
| JP2008514577A (ja) | 2008-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0223380D0 (en) | Combination therapy | |
| IL191796A0 (en) | Combination of zd6474 and pemetrexed | |
| MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
| WO2006035204A3 (en) | Combination comprising zd6474 and an imatinib | |
| MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
| IL191797A0 (en) | Combination of azd2171 and pemetrexed | |
| MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
| MX2007005356A (es) | Terapia de combinacion que comprende zd6474 y un antiadrogenico. | |
| IL172683A0 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| GB0406446D0 (en) | Combination therapy | |
| GB0406445D0 (en) | Combination therapy | |
| IL172682A0 (en) | Combination therapy | |
| WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent | |
| WO2007003933A3 (en) | Combination therapy of cancer with azd2171 and gemcitabine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |